Sussex Formulary

Drug Status Key

  • Non-Specialist Drugs
  • Specialist recommendation (or initiation where noted)
  • Specialist Initiation WITH Shared Care Guidelines
  • Specialist ONLY Drugs
  • Mixed Status - See individual drug entries for more details

Preferences

  • First Line
  • Second Line
  • Third Line
  • No Preference

Cerliponase alfa

{ Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Commissioned by NHS England as per NICE HST12.

Cerliponase alfa 150mg/5ml solution for infusion vials

Pack
2 vial

Brineura 150mg/5ml solution for infusion vials

Pack
2 vial

Inotersen

{ Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Commissioned by NHS England as per NICE HST9 - Inotersent For treating hereditary transthyretin amyloidosis

Inotersen 284mg/1.5ml solution for injection pre-filled syringes

Pack
1 pre-filled disposable injection
4 pre-filled disposable injection

Paraldehyde

{ Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Tafamidis

{ Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Vutrisiran

{ Value = NICE, Index = 0 } { Value = EMC, Index = 3 }

Commissioned by NHS England.

Vutrisiran can be used, within its marketing authorisation, as an option to treat wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults. (NICE TA1115)

Vutrisiran 25mg/0.5ml solution for injection pre-filled syringes

Pack
1 pre-filled disposable injection